TD Cowen has initiated formal coverage of Akoustis Technologies (NASDAQ: AKTS) with a Buy recommendation, according to a research note made public on Tuesday. The brokerage highlighted the company’s miniprotein technology as a vehicle to enter what the analyst described as radiotherapy white space within the healthcare sector.
The note, penned by analyst Tyler Van Buren, points to two lead candidates - AKY’1189 (targeting Nectin-4) and AKY-2519 (targeting B7-H3) - as having demonstrated sustained tumor retention while limiting exposure to healthy tissues. Van Buren emphasized that those attributes could lower the clinical risk associated with forthcoming studies.
TD Cowen’s model anticipates combined 2035 sales for the two products to top $5 billion, a projection that underpins the firm’s constructive stance on the equity. The research communication also expressed confidence in the company’s executive team, describing leadership as world-class and stating that the team should be able to execute on the stated strategic priorities.
Market signals present a mixed picture. At the time the note was released, AKTS was trading at $21.98. InvestingPro Fair Value estimates indicate the share price may be above fair value, and the stock’s relative strength index points toward overbought conditions.
In related coverage, JPMorgan has also initiated research on Akoustis Technologies, assigning an Overweight rating and establishing a $30 price target. That bank characterized the company as a promising platform for developing radiopharmaceutical therapies and expects those therapies to gain meaningful traction over the coming years.
Investor interest in the radiopharmaceutical and oncology space has shown up in public markets recently. Aktis Oncology, listed on the Nasdaq Global Market, opened trading at $27, representing a 50% increase over its initial public offering price of $18 per share. The company increased its IPO share count to 17.65 million from the initially planned 11.8 million, and priced the offering at the top of its marketed range, signaling strong demand.
Together, the analyst initiations and the robust IPO reception illustrate heightened investor activity in radiopharmaceutical development and related oncology platforms. While brokers are publishing optimistic revenue scenarios and positive ratings, valuation metrics and technical indicators highlight near-term caution for market participants evaluating AKTS shares.